A co-expressed Penaeus stylirostris densovirus (PstDNV) capsid and dsRNA specific to the yellow head virus (YHV) protease (CoEx cpPstDNV/dspro) has been shown to suppress YHV replication in the Pacific white-legged shrimp (Litopenaeus vannamei). However, maintaining two plasmids in a single bacterial cell is not desirable; therefore, a single plasmid harboring both the PstDNV capsid and the dsRNA-YHV-pro gene was constructed under the regulation of a single T7 promoter, designated pET28a-Linked cpPstDNV-dspro. Following induction, this novel construct expressed an approximately 37-kDa recombinant protein associated with a roughly 400-bp dsRNA (Linked cpPstDNV-dspro). Under a transmission electron microscope, the virus-like particles (VLP; Linked PstDNV VLPs-dspro) obtained were seen to be monodispersed, similar to the native PstDNV virion. A nuclease digestion assay indicated dsRNA molecules were both encapsulated and present outside the Linked PstDNV VLPs-dspro. In addition, the amount of dsRNA produced from this strategy was higher than that obtained with a co-expression strategy. In a YHV infection challenge, the Linked PstDNV VLPs-dspro was more effective in delaying and reducing mortality than other constructs tested. Lastly, the linked construct provides protection for the dsRNA cargo from nucleolytic enzymes present in the shrimp hemolymph. This is the first report of a VLP carrying virus-inhibiting dsRNA that could be produced without disassembly and reassembly to control virus infection in shrimp.
Significant challenges to poultry health are posed by chicken anemia virus (CAV), which induces immunosuppression and causes increased susceptibility to secondary infections. The effective management and containment of CAV within poultry stocks require precise and prompt diagnosis. However, a deficiency persists in the availability of low-cost, rapid, and portable CAV detection devices. In this study, an immunochromatographic lateral-flow test strip-based assay was developed for CAV detection using in-house generated monoclonal antibodies (MABs) against CAV viral protein 1 (VP1). The recombinant truncated VP1 protein (Δ60VP1), with amino acid residues 1 to 60 of the native protein deleted, was produced via a prokaryotic expression system and utilized for immunizing BALB/c mice. Subsequently, high-affinity MABs against Δ60VP1 were generated and screened using conventional hybridoma technology combined with serial dilution assays. Two MABs, MAB1, and MAB3, both binding to distinct epitopes of Δ60VP1, were selected for the development of a lateral-flow assay. Sensitivity analysis demonstrated that the Δ60VP1 antigen could be detected by our homemade lateral-flow assay at concentrations as low as 625 ng/mL, and this sensitivity was maintained for at least 6 mo. The assay exhibited high specificity, as evidenced by its lack of reactivity with surrogate recombinant proteins and the absence of cross-reactivity with other chicken viruses and viral antigens. Comparative analysis with quantitative PCR data demonstrated substantial agreement, with a Kappa coefficient of 0.66, utilizing a sample set comprising 305 clinical chicken serum samples. In conclusion, the first lateral-flow assay for CAV detection was developed in this study, utilizing 2 specific anti-VP1 MABs. It is characterized by simplicity, rapidity, sensitivity, and specificity.
Lumpy skin disease (LSD), caused by Capripoxvirus, poses significant threats to global livestock due to its high contagion and economic impact. Current diagnostic methods are limited by their dependence on laboratories, while vaccine efficacy monitoring relies on cumbersome virus neutralization tests (VNTs). To address these challenges, a laser-induced graphene (LIG)-based electrochemical immunoassay has been developed for the sensitive detection of LSD and the validation of vaccination. The platform employs recombinant F13L antigen and IgM antibody, configured for dual applications: F13L quantification via IgM-functionalized electrodes and antibody detection using F13L-immobilized surfaces. The biosensor demonstrated exceptional performance, achieving a linear dynamic range of 0.5-5,000 ng mL-1 (R2 = 0.9899) with limits of detection of 0.29 ng mL-1 for F13L detection and 0.05-300 μg mL-1 (R2 = 0.9875) with limits of detection of 0.04 μg mL-1 for IgM detection. A pilot clinical validation with 25 bovine sera (naïve, vaccinated, and naturally infected) yielded preliminary estimates of 95% sensitivity and 100% specificity, correlating with ELISA (R2 = 0.9387). The 10-min readout and <10% signal loss after 30 days of storage support feasibility in field use. These findings provide feasibility evidence that the platform can support point-of-care LSD surveillance and vaccination assessment. Larger, diverse cohorts are warranted to establish generalizable performance.
10 March 2026 in Egyptian Journal of Aquatic Research
Rabies remains a major public health concern in Thailand. Nucleoprotein (N) and glycoprotein (G) genes from eight rabies-positive specimens collected during 2022 to 2024 were sequenced using Oxford Nanopore. Assemblies and phylogenetic analyses indicate genetic diversity with placement in the Asian-SEA3 lineages, supporting ongoing genomic surveillance.